D-0871-2023 Class III Terminated

Recalled by Amring Pharmaceuticals Inc — Berwyn, PA

FDA drug recall D-0871-2023 was initiated by Amring Pharmaceuticals Inc on Jun 12, 2023 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity. The recall status is terminated (terminated May 29, 2024). Affected quantity: 48,989 bottles.

Recall details

Product Type
Drugs
Report Date
Jun 21, 2023
Initiation Date
Jun 12, 2023
Termination Date
May 29, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
48,989 bottles

Product description

Lysteda (tranexamic acid) USP Tablets, 650 mg, 30 tablets per bottle, Rx Only, Manufactured for: Amring Pharmaceuticals Inc. Berwyn, PA 19312, NDC 69918-301-30

Reason for recall

Failed Impurities/Degradation Specifications: Out of specification results obtained for conductivity.

Distribution pattern

Nationwide in the USA.

Code information

Lots: X220317A and X220318A, exp. date 09/25

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0871-2023
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0871-2023. Report a data issue: hello@regdatalab.com.